Navigation Links
Cell Therapeutics, Inc. (CTI) Reports Recent Accomplishments and Third Quarter 2007 Financial Results
Date:11/7/2007

studies. Brostallicin had predictable and predominantly hematologic toxicities. Activity was demonstrated in a number of solid tumor types. A phase II study of brostallicin in relapsed/refractory soft tissue sarcoma met its pre-defined activity and safety hurdles and resulted in a first-line phase II study that is currently being conducted by the European Organization for Research and Treatment of Cancer (EORTC).

Brostallicin was discovered at Pharmacia and developed by Nerviano Medical Sciences (NMS) the largest pharmaceutical research and development facility in Italy and one of the largest oncology-focused, integrated discovery and development companies in Europe. Following a merger between Pfizer and Pharmacia, the rights to brostallicin were assigned to NMS which continued its development and ultimately licensed worldwide rights to Systems Medicine.

About Systems Medicine (SM)

In July 2007, CTI acquired Systems Medicine (SM), a privately held oncology company, in a stock-for-stock merger. SM applies a systems biology approach to drug development, combining pharmacogenomics and bioinformatics with experienced preclinical, clinical, and regulatory expertise to find and exploit a specific cancer's context of vulnerability. Specifically, SM defines the molecular and genetic alterations (context) that cause cancer cells to be particularly sensitive (vulnerable) to a drug or combination of drugs-the context of vulnerability.

About Cell Therapeutics, Inc.

Headquartered in Seattle, CTI is a biopharmaceutical company committed to developing an integrated portfolio of oncology products aimed at making cancer more treatable. For additional information, please visit http://www.cticseattle.com.

This press release includes forward-looking statements that involve a number of risks and uncertainties, the outcome of which could materially and/or adversely affect actual future results. Spe
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine news :

1. Cell Therapeutics, Inc. (CTI) to Present at BIO Investor Forum
2. Horizon Therapeutics, Inc. Scheduled to Present at Upcoming BioPartnering Europe Meeting
3. Sontra Medical Corporation Changes Name to Echo Therapeutics, Inc.
4. Cell Therapeutics, Inc. (CTI) CIBC and Rodman & Renshaw Healthcare Conference Presentations to be Webcast
5. Cell Therapeutics, Inc. (CTI) to Report Third Quarter Financial Results on November 8
6. New Study Reports High Injury Rates for Hotel Workers, Even Higher Rates for Women and Nonwhites
7. Haemacure Reports Third Quarter 2007 Results
8. First-Ever List of the 5,000 Fastest-Growing Businesses Reports Total Revenue of $194.5 Billion
9. Consumer Reports Analysis: Drugs for Nerve Pain, Fibromyalgia Effective, But Not Always Best
10. MDS Reports Third Quarter 2007 Results
11. Allied Healthcare Reports Strong Fourth Quarter, Flat Net Income for Fiscal 2007 vs. 2006
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... OnChip Devices , a world leader ... bondable, silicon ESD (Electrostatic Discharge) protection diodes targeted for ... ESD88NP and ESD88PN are designed to ... IC products. These Zeners exhibit no device degradation ... meet the requirements of IEC61000 and safely dissipate ESD ...
(Date:2/27/2015)... Those who self-injure, commonly ... misdiagnosed and therefore aren’t receiving effective treatment ... Jacksonville-based addiction treatment center Lakeview Health has ... Lakeview Professional Lecture Series to counselors, physicians, ... complicated condition. , “Self-injurious behaviors ...
(Date:2/27/2015)... 27, 2015 Clinovo, a leading provider ... Electronic Data Capture (EDC) at the CALBIO2015 ... 2nd and March 3rd at Booth # 141. ... DIY CRF and edit-check builder allowing Clinical Trials Managers ... of days, without any programming experience. Clinovo’s new pricing ...
(Date:2/27/2015)... 27, 2015 Pipette.com announces their limited ... price is only valid until the end of March ... for a vortex mixer that allows for absolute control ... in 1954 and is headquartered in Bohemia, New York. ... as well as other rockers, incubators, and hybridization ovens ...
(Date:2/27/2015)... February 27, 2015 Undocumented farmworkers ... documented to use Medicaid, the federal health insurance ... to a new study from UC Davis Health ... predictor of farmworker use of Medicaid, which provides ... of documentation status, was having children. , ...
Breaking Medicine News(10 mins):Health News:OnChip Introduces New Series of Space Saving Bare-die Zener Diodes for Transient Voltage Suppression 2Health News:OnChip Introduces New Series of Space Saving Bare-die Zener Diodes for Transient Voltage Suppression 3Health News:Lakeview Health to Host Important Workshop Tackling the Rising Issue of ‘Cutters’ on March 27 2Health News:Clinovo to Demo Its Self-Service, Cloud-Based EDC Solution at CALBIO2015 on March 2nd and 3rd, 2015 2Health News:Pipette.com Announces Limited Time Offer of 24% Off List Price on the Vortex-Genie 2 2Health News:UC Davis Study Finds Undocumented Farmworkers Use Medicaid Half as Often as Documented Farmworkers 2Health News:UC Davis Study Finds Undocumented Farmworkers Use Medicaid Half as Often as Documented Farmworkers 3
... toxins enter the cells, but before the toxins can kill, ... brain cancer cells are even better than healthy cells at ... cells tend to die before brain cancer cells. Especially in ... the University of Colorado Cancer Center have discovered a way ...
... an HIV-infected partner is the single most important factor influencing ... a multinational study of heterosexual couples in sub-Saharan Africa. The ... calculated the risk of HIV-1 transmission per act of sexual ... about 1 per 900 coital acts. The findings also confirmed ...
... The ideal number of embryos to implant during in-vitro fertilization ... be more than three, according to a new study that ... about 124,000 IVF cycles that resulted in 33,500 live births. ... ages who had two embryos implanted than among those who ...
... News) -- A genetic mutation that causes a rare ... has been identified by scientists. Symptoms of the ... hives (cold urticaria), according to the report published online ... England Journal of Medicine . The U.S. National ...
... News) -- A small study that offers new insight into ... effective treatments for people with drinking problems. Researchers used ... alcohol in the brains of 13 heavy drinkers and a ... In all of the participants, drinking alcohol triggered the ...
... MADISON Placing a stent in a key artery in the ... standard surgical treatment of carotid artery disease, according to a ... Vascular Surgery . A team of researchers led ... at University of Wisconsin School of Medicine and Public Health, ...
Cached Medicine News:Health News:Selectively stopping glutathione sensitizes brain tumors to chemotherapy 2Health News:Viral load a major factor affecting risk of sexually transmitting HIV 2Health News:Viral load a major factor affecting risk of sexually transmitting HIV 3Health News:Three Embryos Are Too Many for IVF: Study 2Health News:Gene Research Sheds Light on Rare Immune Disease 2Health News:Alcohol Targets Brain 'Reward Centers' in Heavy Drinkers 2Health News:Stenting for stroke prevention becoming safer in high-risk patients 2
(Date:2/27/2015)... , Feb. 27, 2015  Organovo Holdings, Inc. ... focused on delivering breakthrough 3D bioprinting technology, announced ... Chief Executive Officer, will present live at VirtualInvestorConferences.com ... you to join us for this Company update," ... on our commercial launch of the exVive3D Liver, ...
(Date:2/27/2015)... 2015  Uroplasty, Inc. (NASDAQ: UPI ), a ... proprietary products to treat voiding dysfunctions, today announced that ... on Tuesday, March 10, 2015. Rob Kill , ... Financial Officer, will present at 4:00 p.m. Pacific Time ... conference at the Ritz Carlton in Laguna ...
(Date:2/27/2015)... NEWTON, Mass. and JERUSALEM ... privately-held biopharma company developing octreotide capsules, its lead product ... of a $70 million Series E financing round. Participants ... and Sofinnova Ventures, and an undisclosed blue chip public ... F2 Capital, 7 Med Health Ventures, Abingworth and ARCH ...
Breaking Medicine Technology:Organovo Holdings, Inc. to Provide Corporate Update and Investor Presentation in a Live, Interactive Webcast on March 5th 2Organovo Holdings, Inc. to Provide Corporate Update and Investor Presentation in a Live, Interactive Webcast on March 5th 3Organovo Holdings, Inc. to Provide Corporate Update and Investor Presentation in a Live, Interactive Webcast on March 5th 4Uroplasty to Participate in the 27th Annual ROTH Conference 2Chiasma Announces Completion of $70 Million Series E Financing 2Chiasma Announces Completion of $70 Million Series E Financing 3
... Inc. (NASDAQ: UPI ), a medical ... proprietary products to treat voiding dysfunctions, today announced ... covering the stimulator used in the Urgent® PC ... an office-based, non-surgical system, used to treat overactive ...
... LCAV ), a leading provider of laser vision correction ... management will present at the Lazard Capital Markets 8th Annual ... Eastern time. The conference is being held at the Pierre ... of the presentation will be available at the Investor Relations ...
Cached Medicine Technology:Uroplasty Announces Issuance of New Apparatus Patent for the Urgent® PC Neuromodulation System Stimulator 2
Performa cemented stem....
M2 cemented hip stem....
Porous foundation 480 series....
Cemented foundation 460 series....
Medicine Products: